Pharmena (WAR:PHR) Moat Score: 0/10 (As of Jul. 11, 2026)


WAR:PHR Pharmena SA WAR:PHR
54 GF Score
Price zł3.15
GF Value zł5.72
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Pharmena Moat Score?

Pharmena has the Moat Score of 0, which implies that the company might have No Moat - No discernible moat.

Pharmena has

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Pharmena might have No Moat - No discernible moat.

Pharmena  (WAR:PHR) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Pharmena Moat Score Related Terms

WAR:PHR
54GF Score
Pharmena SA WAR:PHR
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Pharmena (WAR:PHR) Overvalued in 2026?

Based on GuruFocus' analysis, Pharmena stock appears to be undervalued. The current stock price of zł3.15 is trading 44.9% below its estimated GF Value™ of zł5.72. GuruFocus considers Pharmena to be Possible Value Trap.

Key valuation signals for WAR:PHR:

  • Moat Score: 0
  • GF Value™: zł5.72 vs. price of zł3.15 (44.9% below fair value)
  • GF Score™: 54/100 with 4 warning signs

No single metric tells the full story. See the WAR:PHR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pharmena Business Description

Address Ulica Wolczanska 178, Lodz, POL, 90-530
Pharmena SA produces cosmeceuticals and pharmaceuticals. The company's activity focuses on three areas such as research in the USA and Canada on the application of selected pyridinium salts in medicine in order to develop an anti-atherosclerosis drug on a global scale, Production and sales of innovative patented dermocosmetics and introduction into the market of an innovative dietary supplement for atherosclerosis prophylaxis. Its products include Menavitin, Dermena, Allerco and Thermi.
54GF Score

Get the complete analysis for WAR:PHR

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł3.15
Price
zł5.72
GF Value